Program

Check back for updates on the 2019 Genitourinary Cancers Symposium program.

The 2019 Genitourinary Cancers Symposium will feature an array of multidisciplinary sessions covering prostate, renal, urothelial, penile, testicular, and adrenal cancers. World-renowned faculty will present on the most clinically relevant topics across these disease sites with an emphasis on multimodality therapy and value in cancer care.

7:00 AM-7:45 AM Complimentary Continental Breakfast
7:00 AM-6:30 PM Exhibits Open
7:45 AM-9:30 AM

Welcome and General Session 1: Optimizing Diagnosis and Treatment of Clinically Significant Nonmetastatic Prostate Cancer

Jason A. Efstathiou, MD, DPhil—Chair
Massachusetts General Hospital

Himisha Beltran, MD—Chair
Dana-Farber Cancer Institute

Daniel A. Hamstra, MD, PhD
William Beaumont Oakland University Medical School and Beaumont Health (Dearborn)
Welcome

Andrew Vickers, PhD
Memorial Sloan Kettering Cancer Center
PSA Screening: Towards a Harm-Reduction Approach

Samir Taneja, MD
New York University
Role of MRI in Targeted Biopsy

Felix Y. Feng, MD
University of California, San Francisco
Advanced Imaging and Biomarkers for Clinical Decision Making: Where are we now?
 

Abstract 1: PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).
First Author: Nicholas John Van As, MBBCH, MRCP, FRCR, MD(res)

 

Panel Question and Answer

Intensification Versus Deintensification in High-Risk Prostate Cancer

Srikala S. Sridhar, MD, FRCPC
Princess Margaret Cancer Centre, University Health Network
Medical Oncologist

Alberto Briganti, MD, PhD
Vita-Salute San Raffaele University
Urologist

Heather Ann Payne, MBBS, FRCP, FRCR
University College London Hospitals NHS Foundation Trust
Radiation Oncologist

Panel Question and Answer

9:30 AM-10:00 AM Break
10:00 AM-11:30 AM

General Session 2: Quality, Value, and Science for Optimizing Advanced Prostate Cancer Treatment

Karen E. Knudsen, PhD—Chair
Sidney Kimmel Cancer Center at Jefferson

Charles J. Ryan, MD—Chair
University of Minnesota

Beyond Survival: Clinical Decision-Making for Castrate-Sensitive Prostate Cancer

Alicia K. Morgans, MD, MPH
Northwestern University
Quality of Life-Focused Decision-Making for Castrate-Sensitive Prostate Cancer

Ronald C. Chen, MD, MPH
University of North Carolina at Chapel Hill
Value-Based Decision-Making for Castrate-Sensitive Prostate Cancer

Himisha Beltran, MD
Dana-Farber Cancer Institute
Biologic Basis for Sequencing Novel Treatments for Metastatic Prostate Cancer

 

Mark A. Rubin, MD
University of Bern
Practical Application of Genomic Assays in Clinical Decision Making


Abstract 139: Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w) versus every 12 weeks (q12w)—SAKK 96/12 (REDUSE).
First Author: Silke Gillessen, MD
 

Panel Question and Answer

11:30 AM-1:00 PM Poster Session A: Prostate Cancer
With Complimentary Boxed Lunch
11:30 AM-1:00 PM Trials in Progress Poster Session A: Prostate Cancer
With Complimentary Boxed Lunch
11:45 AM-12:45 PM

Trainee and Early-Career Networking Luncheon

 

Toni K. Choueiri, MD—Chair
Dana-Farber Cancer Institute

 

Ananya Choudhury, MA, PhD, MRCP, FRCR
The Christie NHS Foundation Trust and University of Manchester

 

Silke Gillessen, MD
Manchester Cancer Research Centre

 

Karen E. Hoffman, MD, MPH
The University of Texas MD Anderson Cancer Center

 

Christopher J. Kane, MD
University of California, San Diego

 

Karen E. Knudsen, PhD
Sidney Kimmel Cancer Center at Jefferson

 

Bridget F. Koontz, MD
Duke University Medical Center

 

Rana R. McKay, MD
University of California, San Diego

 

Alicia K. Morgans, MD, MPH
Northwestern University

 

Michael J. Morris, MD
Memorial Sloan Kettering Cancer Center

 

Sarah P. Psutka, MD, MS
University of Washington Medical Center

 

Brian M. Shuch, MD
University of California, Los Angeles

1:00 PM-2:35 PM

Oral Abstract Session A: Prostate Cancer
 

Paul L. Nguyen, MD—Chair
Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School

Daniel W. Lin, MD—Chair
University of Washington

Abstract 142: Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
First Author: Padmanee Sharma, MD, PhD

Abstract 143: Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.
First Author: Howard I. Scher, MD, FASCO

William Kevin Kelly, DO
Sidney Kimmel Cancer Center at Thomas Jefferson University
Discussion

Abstract 140: ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).
First Author: Karim Fizazi, MD, PhD

Abstract 141: Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).
First Author: Karim Fizazi, MD, PhD

Abstract 687: Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
First Author: Andrew J. Armstrong, MD

Ian D. Davis, MBBS, PhD, FRACP, FAChPM​
Monash University Eastern Health Clinical School
Discussion

Panel Question and Answer

2:35 PM-3:00 PM Break
3:00 PM-4:30 PM

General Session 3: Collaborative Management of Oligometastatic and Recurrent Prostate Cancer

Francesco Montorsi, MD—Chair
Universita Vita Salute San Raffaele

Michael J. Morris, MD—Chair
Memorial Sloan Kettering Cancer Center

 

Abstract 2: A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer.
First Author: Scott Williams, MD

Tumor Board: Oligometastatic Disease

Gert de Meerleer, MD, PhD
Gent University Hospital
Radiation Oncologist

Bridget F. Koontz, MD
Duke University Medical Center
Radiation Oncologist

Francesco Montorsi, MD
Universita Vita Salute San Raffaele
Urologist

Edward M. Schaeffer, MD, PhD
Northwestern University Feinberg School of Medicine
Urologist

Silke Gillessen, MD
Manchester Cancer Research Centre
Medical Oncologist

Michael J. Morris, MD
Memorial Sloan Kettering Cancer Center
Medical Oncologist

Panel Question and Answer

4:35 PM-5:30 PM Rapid Abstract Session A: Prostate Cancer
Nicholas J. van As, MBBCH, MRCP, FRCR, MD(res)—Chair

Institute of Cancer Research and The Royal Marsden NHS Foundation Trust

Abstract 144: Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).
First Author: Eric Jay Small, MD, FASCO

Question and Answer

Abstract 145: Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Evan Y. Yu, MD

Question and Answer

Abstract 146: Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer.
First Author: William S. Chen, BS

Question and Answer

Abstract 147: Cost-effectiveness of metastasis-directed therapy in the setting of oligometastatic hormone-sensitive prostate cancer.
First Author: Neil Rohit Parikh, MD, MBA

Question and Answer

Abstract 148: A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
First Author: Orazio Caffo, MD

Question and Answer
5:30 PM-6:30 PM Poster Session A: Prostate Cancer
Reception With Complimentary Wine and Cheese
5:30 PM-6:30 PM Trials in Progress Poster Session A: Prostate Cancer
Reception With Complimentary Wine and Cheese
5:45 PM- 6:30 PM Poster Walks

William L. Dahut, MD—Poster Walk Leader

National Cancer Institute

Nicholas J. van As, MBBCH, MRCP, FRCR, MD(res)—Poster Walk Leader
Institute of Cancer Research and The Royal Marsden NHS Foundation Trust